WE ARE TARGETING PAIN AT ITS SOURCE
Virpax Pharmaceuticals specializes in developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance
and optimize the ability of each non-addictive product in our pipeline.
Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing non-opioid and non-addictive pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from postoperative pain to the treatment of acute and chronic pain.
Virpax has global rights to a patented metered-dose topical spray film delivery technology for musculoskeletal pain.
Virpax has worldwide rights to a patented injectable “local anesthetic” liposomal hydrogel technology for postoperative pain management.
Virpax has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain, including pain associated with cancer.
Virpax® Pharmaceuticals is a publicly held company (Nasdaq: VRPX) located in Berwyn, PA and is focused on the development and commercialization of its non-addictive and neurological pipeline.
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic. Virpax will utilize our drug delivery technologies to develop a pipeline of proprietary prescription candidates for commercialization.
OUR MISSION
Our mission is to improve widely used and newly developed non-addictive pain medicines, as well as neurological product candidates, by optimizing our proprietary delivery systems.
We want to provide healthcare professionals and patients with practical solutions to manage pain and neurological issues while helping prescribers facilitate better outcomes worldwide.
EXPERIENCED
EXECUTIVE LEADERSHIP
ROBUST
PIPELINE
Epoladerm™
Diclofenac metered-dose spray film
Epoladerm nonclinical studies have demonstrated improved drying times and less messy handling compared to topical gels/ointments. It’s an invisible application, therefore, more aesthetically appealing. Its pliable application allows for optimized use on joints and other contours of the body.
Probudur™
Injectable long-acting bupivacaine hydrogel
Virpax will introduce its proprietary Probudur, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; 24 hours longer than any other liposomal bupivacaine.
